UroGen Pharma announced the FDA accepted the company’s investigational new drug, or IND, application for UGN-103, a next-generation novel mitomycin-based formulation for low-grade intermediate-risk non-muscle invasive bladder cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma files patent infringement action against Teva Pharmaceuticals
- UroGen Pharma price target lowered to $34 from $35 at Oppenheimer
- Urogen Pharma’s UGN-102 Faces Crucial Test: Durability of Response Key to Drug’s Approval Prospects
- URGN Upcoming Earnings Report: What to Expect?
- UroGen Pharma to Present at TD Cowen Health Care Conference